Brief: Lotus Pharmaceutical Says Lenalidomide, Its Blood Cancer Drug, Has Been Officially Launched In The U.S.
05/09/2022 02:59
Sept 5 (Reuters) - Lotus Pharmaceutical Co Ltd 1795.TW :
* SAYS LENALIDOMIDE, ITS BLOOD CANCER DRUG, HAS BEEN
OFFICIALLY
LAUNCHED IN THE U.S. FOLLOWING SETTLEMENT AGREEMENT WITH
ORIGINAL MANUFACTURER
Source text for Eikon: ID:nMOP5tzjRf
Further company coverage: 1795.TW
(Reporting by Hong Kong newsroom)
((donny.kwok@thomsonreuters.com; +852 3462 7745;))
Recent news on Lotus Pharmaceutical
See all newsMedia: PTT is said to consider options for Taiwan-listed Lotus Pharma - Bloomberg News
Brief: enz Therapeutics Submits NDA for LNZ100 (Vizz) in South Korea to Treat Presbyopia
Brief: Lotus Pharmaceutical Says Unit Has Closed Deal In Vietnam
Brief: Fuji Pharma: Marketing Approval For Generic Lenalidomide, The First Collaboration Product With Taiwan's Lotus
Brief: Amarin And Lotus Pharmaceuticals Announce Exclusive Partnership In Southeast Asia And South Korea